BioLife Solutions/$BLFS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About BioLife Solutions
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Ticker
$BLFS
Sector
Primary listing
Employees
159
Headquarters
Website
BLFS Metrics
BasicAdvanced
$1.2B
-
-$0.07
1.93
-
Price and volume
Market cap
$1.2B
Beta
1.93
52-week high
$29.62
52-week low
$19.10
Average daily volume
368K
Financial strength
Current ratio
4.662
Quick ratio
3.308
Long term debt to equity
3.112
Total debt to equity
5.845
Interest coverage (TTM)
-189.08%
Profitability
EBITDA (TTM)
-1.903
Gross margin (TTM)
64.28%
Net profit margin (TTM)
-3.20%
Operating margin (TTM)
-4.53%
Effective tax rate (TTM)
-1.40%
Revenue per employee (TTM)
$630,000
Management effectiveness
Return on assets (TTM)
-0.73%
Return on equity (TTM)
-5.25%
Valuation
Price to revenue (TTM)
12.268
Price to book
3.52
Price to tangible book (TTM)
9.28
Price to free cash flow (TTM)
126.175
Free cash flow yield (TTM)
0.79%
Free cash flow per share (TTM)
0.206
Growth
Revenue change (TTM)
87.53%
Earnings per share change (TTM)
-93.04%
3-year revenue growth (CAGR)
-13.51%
10-year revenue growth (CAGR)
31.87%
3-year earnings per share growth (CAGR)
-69.32%
10-year earnings per share growth (CAGR)
-14.11%
What the Analysts think about BLFS
Analyst ratings (Buy, Hold, Sell) for BioLife Solutions stock.
Bulls say / Bears say
In Q1 2025, BioLife posted US$23.94 million in revenue—5.28% above consensus—and delivered EPS of US$0.04 compared to an expected loss of US$0.03, showing solid revenue momentum and improved operating efficiency. (Nasdaq)
For Q3 2025, the company reached US$28.07 million in revenue (up 31% year-over-year) and EPS of US$0.04, both beating Zacks consensus, indicating strong demand for its main cell processing products. (Nasdaq)
After Q2 2025, BioLife increased its full-year 2025 revenue guidance to US$100.0 million–US$103.0 million—up 22%–25% year-over-year—which shows management’s belief in continued growth. (PR Newswire)
The stock’s valuation is expensive, with a trailing P/E of 148.97 and a forward P/E of 3,087.50, indicating that investor expectations might have already reached their peak. (CNBC)
Cell Processing accounted for roughly 90% of Q3 2025 revenue (US$25.4 million out of US$28.1 million), which signals a high dependence on a single business segment. (PR Newswire)
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2025.
BLFS Financial Performance
Revenues and expenses
BLFS Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioLife Solutions stock?
BioLife Solutions (BLFS) has a market cap of $1.2B as of November 10, 2025.
What is the P/E ratio for BioLife Solutions stock?
The price to earnings (P/E) ratio for BioLife Solutions (BLFS) stock is 0 as of November 10, 2025.
Does BioLife Solutions stock pay dividends?
No, BioLife Solutions (BLFS) stock does not pay dividends to its shareholders as of November 10, 2025.
When is the next BioLife Solutions dividend payment date?
BioLife Solutions (BLFS) stock does not pay dividends to its shareholders.
What is the beta indicator for BioLife Solutions?
BioLife Solutions (BLFS) has a beta rating of 1.93. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.